The invention relates to antibiotic substances of microbial origin, arbitrarily denominated antibiotic GE 811112 factor A, factor B1 and factor B, which are produced by fermentation of Streptomyces sp. DSMZ 14386, the pharmaceutically acceptable salts and composition thereof, and their use as an antibacterial agent having activity versus susceptible microbes.
Drawings
Claims2
Isolated antibiotic GE 81112 Factor B having the following characteristics:
A) Mass spectrum recorded from a 0.01 mg/ml solution in acetonitrile:water 50:50 giving a monoprotonated ion at 659 m/z on a Thermofinnigan LCQ deca instrument under the following electrospray conditions:
Spray Voltage:
4.7 kv;
Capillary temperature:
250° C.;
Capillary Voltage:
9V;
Infusion mode 5 μl/min.
B) Infrared spectrum (FIG. 6) recorded in KBr with an IFS-48 Fourier Transform spectrophotometer showing the following main bands (cm−1):
3359;
2958;
2852;
2258;
2129;
1681;
1591;
1450;
1385;
1347;
1122;
1072;
1025;
998;
765
C) 1H-NMR spectrum (FIG. 7) recorded at 600 MHz at 25° C. in DMSO-d6 and trifluoroacetic acid (drops) showing the following 1H signals:
Chemical shift (ppm)
Multiplicity
1.52
br d
1.57-1.72
m
1.83
br d
1.90
m
2.63
dd
2.88
dd
2.92
m
3.13
br d
3.64
m
3.83
m
3.95
br d
4.35
br s
4.46
m
4.50
dd
4.60
m
5.05
d
6.46
br
6.48
s
6.93
s
7.40
br s
7.84
d
8.05
d
8.33
m
8.54
d
9.00
br d
11.72
br s
11.75
br s
—
—
D) 13C-NMR spectrum (FIG. 8) recorded at 150 MHz, at 25° C. in DMSO-d6 and trifluoroacetic acid (drops) showing the following 13C signals
13C Chemical shift (ppm)
Multiplicity
15.9
t
27.36
t
28.40
t
35.47
t
42.87
t
50.1
d
51.20
d
56.78
d
59.73
d
64.09
d
65.14
d
66.90
d
67.77
t
110.3
d
117.85
d
122.5
s
128.4
s
139.66
s
146.7
s
156.7
s
167.4
s
170.5
s
171.3
s
171.38
s
E) Retention time 21.6 min, determined by using an analytical HPLC Shimadzu LC10-AS, equipped with an “Altima” RP18, 5 μm, 250×4.6 mm i.d column;
isocratic elution performed at 1 ml/min. flow rate, with 40 mM ammonium formate buffer, brought to pH 4.5 by addition of formic acid;
UV detection at 230 nm.
134 more elements
Isolated antibiotic GE 81112 factor B1 having the following characteristics:
A) Mass spectrum recorded from a 0.01 mg/ml solution in acetonitrile:water 50:50 giving a monoprotonated ion at 658 m/z ib a Termofinnigan LCQ deca instrument under the following electrospray conditions;
Spray Voltage:
47 kv;
Capillary Temperature:
250° C.;
Capillary voltage:
9V;
Infusion Mode:
5 1/min.
B) H-NMR spectrum (FIG. 10) recorded at 600 MH at 25° C. in DMSO-d6 showing the following 1H signals:
Chemical shift (ppm)
Multiplicity
1.38
br d
1.56-1.64
m
1.76
m
2.70
m
2.82
br s
2.92
m
3.01-3.06
m
3.49
br m
3.57
br s
4.20
br dd
4.26
br
4.40
br m
4.46
m
5.05
d
5.60
br s
6.21
br
6.52
br
6.78
br s
7.13
br
7.80
br d
7.90
br d
8.44
br
C) 13C-NMR spectrum (FIG. 11) recorded at 150 Mhz, at 25° C. in DMSO-d6 showing the following 13C signals:
Chemical shift (ppm)
Multiplicity
17.95
t
27.97
t
29.8
t
36.54
t
43.75
t
45.65
d
50.52
d
51.9
d
57.75
d
61.0
d
64.03
d
66.7
d
66.88
d
111.07
d
118.97
d
122.47
s
127.88
s
148.08
s
159.18
s
169.44
s
171.53
s
171.81
s
173.08
s
—
—
D) Retention time 18.4 min, determined by using an analytical HPLC Shimadzu LC10-AS, equipped with an “Altima” RP18, 5 μm, 250×4.6 mm i.d column;
isocratic elution performed at 1 ml/min. flow rate, with 40 mM ammonium formate buffer brought to pH 4.5 by addition of formic acid;
11 Sep 2025Estimated · howhide20 years from earliest known nonprovisional domestic filing plus recorded patent term adjustment, including 355 days of adjustment. Maintenance-fee lapses, terminal disclaimers and statutory extensions have not been checked. The continuity chain may be incomplete; this is not an enforceability determination.
In human health protection, e.g. against extreme weather: against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne…
Life of this patent
Term ended 11 Sep 2025 (estimated)
Priority, Europe28 Nov 2001
Filed26 Jun 2008
Published22 Jan 2009
Granted30 Aug 2011
Term ended11 Sep 2025
Priority, Europe28 Nov 2001
Granted30 Aug 2011
Term ended11 Sep 2025
Priority claimedEP 01128204
Application filedUS 12/147,215
PublishedUS 2009/0023665 A1
GrantedUS 8,007,789 B2
Assigned to Pdl Biopharma, Inc.security agreement
Assigned to Vicuron Pharmaceuticals Inc.release of security interest
Term endedEstimated, includes 355 days of adjustment
Description7,551 words
Summary89 words
#The present invention concerns an antibiotic substance of microbial origin, arbitrarily denominated GE 81112 factor A, GE 81112 factor B and GE 81112 factor B1, a mixture of said factors in any proportion, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent.
#Another object of the present invention is a process for preparing GE 81112 factor A, GE 81112 factor B and GE 81112 factor B1, a mixture of said factors in any proportion, hereinafter reported as GE 81112 compounds or GE 81112 antibiotics.
Brief description of the drawings11 figures
#FIG. 1 provides the MsMs spectrum of GE 81112 factor A after fragmentation of the monoprotonated ion at m/z=644 with normalized collisions energy of 25%
#FIG. 2 provides the infrared spectrum of GE 81112 factor A in nujol.
#FIG. 3 provides 1H spectrum of GE 81112 factor A in DMSO-d6 and TFA (drops).
Detailed description7,273 words
#Streptomyces sp. DSMZ 14386 originally designed with the internal code GE 81112 was isolated from a soil sample and deposited on Jul. 16, 2001, with the DSMZ, (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1b, D-38124 Braunschweig, Germany), under the provision of the Budapest Treaty. The strain was accorded accession number DSMZ 14386.
#The production of GE 81112 compounds is achieved by cultivating a Streptomyces strain capable of producing them, i.e. Streptomyces sp. DSMZ 14386 or a variant or mutant thereof maintaining the genetic ability to produce said GE 81112 compounds; isolating the resulting antibiotic from the culture broth; purifying the isolated antibiotic; and separating the antibiotic three factors A, B and B1 or their mixture by chromatographic means. In any case, it is preferred to produce compounds GE 81112 under aerobic conditions in an aqueous nutrient medium containing assimilable sources of carbon, nitrogen, and inorganic salts, purifying the resulting compounds by means of chromatographic techniques. Many of the nutrient media usually employed in the fermentation field can be used, however certain media are preferred.
#Preferred carbon sources are glucose, xilose, starch, fructose, glycerol, and the like. Preferred nitrogen sources are soybean meal, peptone, meat extract, yeast extract, tryptone, aminoacids, hydrolized casein and the like. Among the inorganic salts which can be incorporated in the culture media, there are the customary soluble salts capable of yielding sodium, potassium, iron, zinc, cobalt, magnesium, calcium, ammonium, chloride, carbonate, sulphate, phosphate, nitrate, and the like ions.